Pharma
Ferring Pharmaceuticals
1
Articles
Mentioned
Top Role
Apr 11, 2026
First Mention
Apr 11, 2026
Last Mention
0.96
Relevance Score
Coverage Timeline
April 2026
Currax’s Nocdurna FDA Nod: $400M Branded Disruptor Upends Sleep Disorder Market Playbook
The Week
Mentioned
Apr 11, 2026
Once managed by Ferring in the U.S., Nocdurna topped out at nearly $110 million in American sales before patent fights and half-hearted commercial execution stunted its trajectory.